157 related articles for article (PubMed ID: 16421754)
1. Dihydropyrimidine dehydrogenase deficiency in an Indian population.
Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754
[TBL] [Abstract][Full Text] [Related]
2. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
3. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
6. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
7. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
8. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
Lu Z; Zhang R; Diasio RB
Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
[TBL] [Abstract][Full Text] [Related]
11. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
[TBL] [Abstract][Full Text] [Related]
12. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2008 Jan; 18(1):25-35. PubMed ID: 18216719
[TBL] [Abstract][Full Text] [Related]
13. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
[TBL] [Abstract][Full Text] [Related]
14. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Saif MW; Seller S; Diasio RB
JOP; 2008 Mar; 9(2):226-9. PubMed ID: 18326935
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
Ogura K; Ohnuma T; Minamide Y; Mizuno A; Nishiyama T; Nagashima S; Kanamaru M; Hiratsuka A; Watabe T; Uematsu T
Clin Cancer Res; 2005 Jul; 11(14):5104-11. PubMed ID: 16033824
[TBL] [Abstract][Full Text] [Related]
16. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
17. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
18. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
20. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
